Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis

The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

(2016) Roopinder K. Sandhu et al.   EUROPEAN HEART JOURNAL

Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials

(2015) Matteo Nicola Dario Di Minno et al.   ANNALS OF MEDICINE

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients　– Insight From the Fushimi AF Registry –

(2015) Yasuhiro Hamatani et al.   CIRCULATION JOURNAL

Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry

(2015) Yasuhiro Hamatani et al.   PLoS One

Overweight is associated with improved survival and outcomes in patients with atrial fibrillation

(2014) Juan Wang et al.   Clinical Research in Cardiology

Edoxaban: a focused review of its clinical pharmacology

(2014) G. Y. H. Lip et al.   EUROPEAN HEART JOURNAL

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

(2013) Vijay V. Upreti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

(2013) Sam Schulman et al.   CIRCULATION

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation

(2012) Takeshi Yamashita et al.   CIRCULATION JOURNAL

Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial

(2012) W. Doehner et al.   EUROPEAN HEART JOURNAL

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

The influence of optimal medical treatment on the ‘obesity paradox’, body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study

(2012) Lisanne Schenkeveld et al.   BMJ Open

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Obesity on Outcomes in Atrial Fibrillation: Yet Another Obesity Paradox

(2010) Apurva O. Badheka et al.   AMERICAN JOURNAL OF MEDICINE

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE